HEALTHY SUBJECTS

This early-stage study tests a new medicine called ISH0688, given as a shot under the skin, for people with high triglycerides (a type of blood fat). The study will involve 104 healthy volunteers and people with high triglycerides to check the drug's safety and how the body proce…

This study tests whether three months of flicker stimulation (using near-infrared light or visual occlusion glasses) can improve thinking, movement, and mood in healthy older adults and those with subjective cognitive decline. Sixty participants aged 65-89 will be assigned to dif…

This observational study will use advanced imaging techniques to measure changes in the retina and choroid (the layer beneath the retina) in people with eye diseases and healthy volunteers. Over 5 years, researchers will track thickness and blood vessel density to better understa…

This study will check if a new generic drug called YHP2508C works the same as the reference drug YHR2603 in 44 healthy adults. Participants will take a single dose of each drug under fasting conditions, and researchers will measure drug levels in the blood. The goal is to see if …

This study tests an experimental drug called CM326 in 192 healthy men aged 18 to 55. The goal is to see how the drug moves through the body and if it is safe when given through different injection devices. Participants will receive a single shot and be monitored for side effects …

This study will measure shoulder and grip strength in 120 healthy baseball players to see how shoulder structure (retroversion) and age affect strength. Participants will have their strength tested with a special device. The goal is to better understand shoulder function in athle…

This study tests whether a cosmetic product is safe for the skin. About 26 healthy adults will wear a patch with the product for 48 hours to see if it causes irritation or redness. The goal is simply to check skin compatibility, not to treat any disease.

This early-stage trial tests a single injection of GR2301, an antibody that targets IL15, in 36 healthy adults in China. The main goal is to check safety and how the body processes the drug. Participants are randomly assigned to receive either GR2301 or a placebo, and are monitor…